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Indications for cardiac resynchronization therapy 
(CRT) with defibrillation (CRT-D) versus pacing 
(CRT-P) was challenging in the early 2000s. There were 
many researches to and fro of CRT-D versus CRT-P 
implantation in patients with cardiomyopathy (CMP) 
and left bundle branch block pattern in 
electrocardiography. In 2012, ACC/AHA/HRS 
(American College of Cardiology 
Foundation/American Heart Association Task Force 
on Practice Guidelines and the Heart Rhythm Society) 
guidelines, recommendations for implantable 
cardioverter defibrillator (ICD), was completely apart 
to the indications of CRT[1]. In such guidelines, ICD 
indicated for most of patients with ischemic CMP and 
patients with non-ischemic CMP with high functional 
class. Therefore, ICD simultaneously indicated many 
patients benefitting from CRT. Therefore, the 
indications for CRT-P are very limited according to 
these guidelines [1]. The ESC guideline recommends 
implantation of CRT-P instead of CRT-D only in 
patients with short life expectancy such as the ones with 
advanced renal failure [2]. 
Although left ventricular ejection fraction (LVEF) is an 
excellent practical marker of ventricular arrhythmic 
events, however, only a small percentage of ICD 
recipients receive appropriate ICD therapy [3]. The 
predictors of appropriate ICD therapy markedly vary 
between the studies. Non-sustained ventricular 
tachycardia, abnormal sphericity index, male gender, 
high NYHA (New York Heart Association) functional 
class, and smoking were reported as predictors for 
ventricular arrhythmia in few studies, but still not 
approved as good markers to change the decision [4-6]. 
Recently, the benefit of ICD for patients with dilated 
CMP was doubted in a Danish trial. This trial 
demonstrated that ICD implantation did not have 
survival benefits for patients with symptomatic heart 
failure not caused by coronary artery disease [7]. 
Accordingly, a recent study showed that midwall fibrosis 
detected by magnetic resonance imaging (MRI) may be 
a good predictor for adverse outcomes including 
ventricular tachyarrhythmia and sudden arrhythmic 
death in the patients with non-ischemic CMP; hence, 
CRT-D may be superior to CRT-P in this subgroup of 
patients with non-ischemic CMP [8]. 
On the other hand, in many pacemaker-dependent 
patients, only RV pacing may cause CMP. Kiehl et al., 
showed that incidence of pacemaker-induced 
cardiomyopathy was about 12.3% in patients with 
complete heart block treated with pacemaker; hence, it 
may be necessary to upgrade their device to CRT [9]. 
According to the current AHA and ESC guidelines, 
CRT implantation or upgrading to CRT device is 
observed in patients with high ventricular pacing and 
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LVEF of >35% de nevo [1, 2]. This may explain that why 
through the first decade of this millennium, there was a 
significant de nevo CRT implantation in Europe and the 
United States; however, recently, upgrading of the 
existing pacemakers and ICDs dedicated a larger 
amount of CRT implantation [10]. Khurshid et al., 
showed reversal of pacing induced cardiomyopathy in 
more than 70% of patients after upgrading their device 
to CRT [11]. Therefore, it seems that the mechanism of 
CMP may be reversible especially if managed soon. 
With improvement of LVEF, such patients have no 
indication of ICD, either. 
While there are no high-quality randomized data, 
choosing the device for such patients should be done 
with caution. It is necessary to consider the risks of two-
lead implantation instead of only single LV lead 
placement, more infection risk due to prolonger 
procedure time, and also the cost estimation of the 
decision.  
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